Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 7Phase 1 5Phase 3 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 7Unknown 3Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 129Radiotherapy 94Carboplatin 82Fluorouracil 77Paclitaxel 76Cyclophosphamide 76Gemcitabine 71Capecitabine 66Docetaxel 64Doxorubicin 59Oxaliplatin 57Etoposide 57Leucovorin 48Vincristine 46Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Pemetrexed 27Neoadjuvant Therapy 26Irinotecan 25Tamoxifen 24Prednisone 23Methotrexate 21Rituximab 19Vinorelbine 18Radiotherapy, Intensity-Modulated 18Peripheral Blood Stem Cell Transplantation 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Immune Checkpoint Inhibitors × Clear all
NCT05737563 2024-01-23

Escape

Sun Yat-sen University

Phase 3 Unknown
380 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05374252 2022-05-16

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3 Unknown
102 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04229355 2021-02-09

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Guangxi Medical University

Phase 3 Unknown
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡